Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACLXNASDAQ:AKRONASDAQ:RARENYSE:ZYME On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACLXArcellx$58.25-2.1%$64.11$47.86▼$107.37$3.21B0.34575,695 shs750,802 shsAKROAkero Therapeutics$40.01-3.7%$41.07$17.86▼$58.40$3.19B-0.12894,817 shs990,092 shsRAREUltragenyx Pharmaceutical$35.40-1.9%$36.67$29.59▼$60.37$3.35B0.34825,987 shs705,691 shsZYMEZymeworks$11.61-3.4%$11.82$8.21▼$17.70$807.79M1.24600,686 shs428,154 shs10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACLXArcellx-2.10%+10.39%-1.52%-7.99%+17.04%AKROAkero Therapeutics-3.66%-4.78%+12.17%-19.07%+94.03%RAREUltragenyx Pharmaceutical-1.91%+0.97%+3.69%-18.49%-13.57%ZYMEZymeworks-3.41%-1.11%+9.22%-18.81%+25.65%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACLXArcellx1.6632 of 5 stars3.50.00.00.02.72.50.0AKROAkero Therapeutics3.6731 of 5 stars3.51.00.04.72.71.70.0RAREUltragenyx Pharmaceutical4.3429 of 5 stars4.51.00.03.82.52.50.6ZYMEZymeworks2.3369 of 5 stars3.40.00.00.02.73.30.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACLXArcellx 3.07Buy$111.3391.13% UpsideAKROAkero Therapeutics 3.00Buy$76.0089.95% UpsideRAREUltragenyx Pharmaceutical 2.93Moderate Buy$90.93156.87% UpsideZYMEZymeworks 2.88Moderate Buy$21.0080.88% UpsideCurrent Analyst Ratings BreakdownLatest ZYME, RARE, AKRO, and ACLX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/13/2025AKROAkero TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$80.00 ➝ $78.005/9/2025ACLXArcellxScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Outperform ➝ Sector Outperform$133.00 ➝ $93.005/9/2025RAREUltragenyx PharmaceuticalMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$64.00 ➝ $65.003/27/2025RAREUltragenyx PharmaceuticalJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$104.00 ➝ $117.003/17/2025RAREUltragenyx PharmaceuticalPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$140.00 ➝ $115.003/11/2025ZYMEZymeworksLifesci CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$30.003/10/2025ZYMEZymeworksHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$12.00 ➝ $13.003/7/2025ZYMEZymeworksCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$18.00 ➝ $19.003/3/2025AKROAkero TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$72.00 ➝ $75.003/2/2025AKROAkero TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight2/26/2025RAREUltragenyx PharmaceuticalCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$118.00 ➝ $118.00(Data available from 5/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACLXArcellx$76.81M41.77N/AN/A$9.97 per share5.84AKROAkero TherapeuticsN/AN/AN/AN/A$9.61 per shareN/ARAREUltragenyx Pharmaceutical$590.69M5.67N/AN/A$2.76 per share12.83ZYMEZymeworks$93.38M8.65N/AN/A$6.63 per share1.75Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACLXArcellx-$70.69M-$2.99N/AN/AN/A-25.94%-8.28%-5.21%N/AAKROAkero Therapeutics-$151.76M-$3.75N/AN/AN/AN/A-32.46%-29.83%N/ARAREUltragenyx Pharmaceutical-$569.18M-$5.88N/AN/AN/A-101.60%-193.80%-38.15%N/AZYMEZymeworks-$118.67M-$1.49N/AN/AN/A-182.75%-23.00%-18.04%N/ALatest ZYME, RARE, AKRO, and ACLX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025AKROAkero Therapeutics-$1.01$0.90+$1.91$0.90N/AN/A5/8/2025Q1 2025ACLXArcellx-$0.84-$1.13-$0.29-$1.13$19.51 million$8.13 million5/8/2025N/AZYMEZymeworks-$0.45-$0.30+$0.15N/A$20.65 million$27.11 million5/6/2025Q1 2025RAREUltragenyx Pharmaceutical-$1.54-$1.57-$0.03-$1.57$145.98 million$139.29 million2/28/2025Q4 2024AKROAkero Therapeutics-$0.98-$0.99-$0.01-$0.99N/AN/A2/27/2025Q4 2024ACLXArcellx-$0.63-$0.87-$0.24-$0.87$27.42 million$15.27 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACLXArcellxN/AN/AN/AN/AN/AAKROAkero TherapeuticsN/AN/AN/AN/AN/ARAREUltragenyx PharmaceuticalN/AN/AN/AN/AN/AZYMEZymeworksN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACLXArcellxN/A4.294.29AKROAkero Therapeutics0.0517.2517.25RAREUltragenyx PharmaceuticalN/A2.372.65ZYMEZymeworksN/A4.104.10Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACLXArcellx96.03%AKROAkero TherapeuticsN/ARAREUltragenyx Pharmaceutical97.67%ZYMEZymeworks92.89%Insider OwnershipCompanyInsider OwnershipACLXArcellx6.24%AKROAkero Therapeutics7.94%RAREUltragenyx Pharmaceutical5.50%ZYMEZymeworks1.92%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACLXArcellx8055.07 million50.70 millionOptionableAKROAkero Therapeutics3079.68 million64.26 millionOptionableRAREUltragenyx Pharmaceutical1,31094.54 million86.99 millionOptionableZYMEZymeworks46069.58 million67.56 millionOptionableZYME, RARE, AKRO, and ACLX HeadlinesRecent News About These CompaniesZymeworks Inc. (NYSE:ZYME) Shares Sold by Granahan Investment Management LLCMay 12 at 6:35 AM | marketbeat.comFarallon Capital Management LLC Sells 31,026 Shares of Zymeworks Inc. (NYSE:ZYME)May 11 at 7:40 AM | marketbeat.comDimensional Fund Advisors LP Purchases 123,240 Shares of Zymeworks Inc. (NYSE:ZYME)May 11 at 3:51 AM | marketbeat.comZymeworks May 2025 slides: Pipeline expansion amid modest revenue growthMay 10, 2025 | investing.comZymeworks Inc. Reports Financial Results and Highlights Recent Developments, Including Appointment of Dr. Sabeen Mekan and AACR Poster PresentationsMay 10, 2025 | nasdaq.comZymeworks Inc. (NYSE:ZYME) Q1 2025 Earnings Call TranscriptMay 10, 2025 | msn.comZymeworks Inc. (NYSE:ZYME) Shares Bought by Voya Investment Management LLCMay 10, 2025 | marketbeat.comZymeworks Inc.: Zymeworks Provides Corporate Update and Reports First Quarter 2025 Financial ResultsMay 10, 2025 | finanznachrichten.deZymeworks outlines robust pipeline advancements and financial resilience through 2027May 10, 2025 | msn.comZymeworks Provides Corporate Update and Reports First Quarter 2025 Financial ResultsMay 10, 2025 | finance.yahoo.comZymeworks Inc. (ZYME) Q1 2025 Earnings Call TranscriptMay 9, 2025 | seekingalpha.comZymeworks Inc. 2025 Q1 - Results - Earnings Call PresentationMay 8, 2025 | seekingalpha.comZymeworks Inc. (ZYME) Reports Q1 Loss, Tops Revenue EstimatesMay 8, 2025 | zacks.comBlackstone Inc. Has $8.34 Million Stock Position in Zymeworks Inc. (NYSE:ZYME)May 8, 2025 | marketbeat.comRaymond James Financial Inc. Takes $888,000 Position in Zymeworks Inc. (NYSE:ZYME)May 8, 2025 | marketbeat.comJazz Pharmaceuticals Stock Price, Quotes and ForecastsMay 7, 2025 | benzinga.comZymeworks Inc. (NYSE:ZYME) Shares Sold by BVF Inc. ILMay 6, 2025 | marketbeat.comZymeworks (ZYME) Projected to Post Earnings on ThursdayMay 6, 2025 | americanbankingnews.comZymeworks Inc. (NYSE:ZYME) Receives $21.00 Consensus PT from BrokeragesMay 5, 2025 | americanbankingnews.comAcuta Capital Partners LLC Acquires Shares of 67,240 Zymeworks Inc. (NYSE:ZYME)May 4, 2025 | marketbeat.comInvesco Ltd. Reduces Position in Zymeworks Inc. (NYSE:ZYME)May 4, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesArcher Aviation Gets Analyst Target Upgrade: Time to Load Up?By Jeffrey Neal Johnson | April 25, 2025View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?Why D-Wave's Project With Davidson Is a Game-Changer For QuantumBy Nathan Reiff | April 30, 2025View Why D-Wave's Project With Davidson Is a Game-Changer For QuantumGold Rally Continues: These 3 Mining Stocks Are Likely to BenefitBy Chris Markoch | April 16, 2025View Gold Rally Continues: These 3 Mining Stocks Are Likely to Benefit2 Smart Investments to Follow Warren Buffett’s LeadBy Ryan Hasson | April 23, 2025View 2 Smart Investments to Follow Warren Buffett’s LeadD-Wave Quantum Slides on Chip News: Opportunity to Buy?By Nathan Reiff | April 21, 2025View D-Wave Quantum Slides on Chip News: Opportunity to Buy?ZYME, RARE, AKRO, and ACLX Company DescriptionsArcellx NASDAQ:ACLX$58.25 -1.25 (-2.10%) As of 05/13/2025 04:00 PM EasternArcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company's preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, it focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.Akero Therapeutics NASDAQ:AKRO$40.01 -1.52 (-3.66%) As of 05/13/2025 04:00 PM EasternAkero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.Ultragenyx Pharmaceutical NASDAQ:RARE$35.40 -0.69 (-1.91%) As of 05/13/2025 04:00 PM EasternUltragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.Zymeworks NYSE:ZYME$11.61 -0.41 (-3.41%) As of 05/13/2025 04:00 PM EasternZymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas. Zymeworks Inc. has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; LEO Pharma A/S; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas NVIDIA Stock Surges on Bullish News: How High Could It Climb? NuScale Power in Rebound Mode With Short-Squeeze a Possibility Why Amazon May Never Dip Below $200 Again eBay Nears Big Breakout: Time to Buy the Under-the-Radar Winner? Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for Long Why Boeing May Be Ready to Take Off After Latest Developments Goldman Sachs Warns of 20% Market Sell-Off: Are They Right? 3 Huge S&P 500 Winners From Trump Trade Deal & The Biggest Loser Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
